SREBF2 promotes osteoporosis by activating Hippo/YAP to drive adipogenesis while inhibiting BMP/Smad to suppress osteogenesis in BMSCs. Targeting SREBF2 is a promising therapeutic strategy.
Xiao et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: